Clinical management of uterine papillary serous carcinoma

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol.15(1), 10–17 (1983).
   PubMed Web of Science ®Google Scholar
• Fox H. Endometrial carcinogenesis and its relation to oestrogens. Pathol. Res. Pract.179(1), 13–19 (1984).
   PubMedGoogle Scholar
• Sivridis E, Giatromanolaki A. Prognostic aspects on endometrial hyperplasia and neoplasia. Virchows Arch.439(2), 118–126 (2001).
   PubMed Web of Science ®Google Scholar
• Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv. Anat. Pathol.11(3), 117–142 (2004).
   PubMed Web of Science ®Google Scholar
• Goff BA. Uterine papillary serous carcinoma: what have we learned over the past quarter century? Gynecol. Oncol.98(3), 341–343 (2005).
   PubMed Web of Science ®Google Scholar
• Hamilton CA, Kapp DS, Chan JK. Clinical aspects of uterine papillary serous carcinoma. Curr. Opin. Obstet. Gynecol.20(1), 26–33 (2008).
   PubMed Web of Science ®Google Scholar
• Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol. Oncol.81(1), 92–99 (2001).
   PubMed Web of Science ®Google Scholar
• Cirisano FD Jr, Robboy SJ, Dodge RK et al. The outcome of stage I–II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol. Oncol.77(1), 55–65 (2000).
   PubMedGoogle Scholar
• Nicklin JL, Copeland LJ. Endometrial papillary serous carcinoma: patterns of spread and treatment. Clin. Obstet. Gynecol.39(3), 686–695 (1996).
   PubMedGoogle Scholar
• Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol. Oncol.47(3), 298–305 (1992).
   PubMed Web of Science ®Google Scholar
• Grice J, Ek M, Greer B et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol. Oncol.69(1), 69–73 (1998).
   PubMed Web of Science ®Google Scholar
• Trope C, Kristensen GB, Abeler VM. Clear-cell and papillary serous cancer: treatment options. Best Pract. Res. Clin. Obstet. Gynaecol.15(3), 433–446 (2001).
   PubMedGoogle Scholar
• Kato DT, Ferry JA, Goodman A et al. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol. Oncol.59(3), 384–389 (1995).
   PubMed Web of Science ®Google Scholar
• Piura B, Meirovitz M, Shmulman M, Yanai-Inbar I, Cohen Y, Dgani R. Uterine papillary serous carcinoma: study of 19 cases. Eur. J. Obstet. Gynecol. Reprod. Biol.79(1), 69–73 (1998).
   PubMedGoogle Scholar
• Bristow RE, Asrari F, Trimble EL, Montz FJ. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (stage I–III) disease. Gynecol. Oncol.81(2), 279–286 (2001).
   PubMed Web of Science ®Google Scholar
• Creasman WT, Kohler MF, Odicino F, Maisonneuve P, Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol. Oncol.95(3), 593–596 (2004).
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Burke TW, Eifel PJ et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol. Oncol.91(3), 463–469 (2003).
   PubMed Web of Science ®Google Scholar
• Geisler JP, Geisler HE, Melton ME, Wiemann MC. What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol. Oncol.74(3), 465–467 (1999).
   PubMed Web of Science ®Google Scholar
• Amant F, Cadron I, Fuso L et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol. Oncol.98(2), 274–280 (2005).
   PubMed Web of Science ®Google Scholar
• Cirisano FD Jr, Robboy SJ, Dodge RK et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol. Oncol.74(3), 385–394 (1999).
   PubMed Web of Science ®Google Scholar
• Gehrig PA, Groben PA, Fowler WC Jr, Walton LA, Van LL. Noninvasive papillary serous carcinoma of the endometrium. Obstet. Gynecol.97(1), 153–157 (2001).
   PubMed Web of Science ®Google Scholar
• Dunton CJ, Balsara G, McFarland M, Hernandez E. Uterine papillary serous carcinoma: a review. Obstet. Gynecol. Surv.46(2), 97–102 (1991).
   PubMedGoogle Scholar
• Sood BM, Jones J, Gupta S et al. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int. J. Radiat. Oncol. Biol. Phys.57(1), 208–216 (2003).
   PubMedGoogle Scholar
• Fader AN, Nagel C, Axtell AE et al. Stage II uterine papillary serous carcinoma: carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol. Oncol.112(3), 558–562 (2009).
   PubMed Web of Science ®Google Scholar
• Goff BA, Kato D, Schmidt RA et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol. Oncol.54(3), 264–268 (1994).
   PubMed Web of Science ®Google Scholar
• Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am. J. Surg. Pathol.6(2), 93–108 (1982).
   PubMed Web of Science ®Google Scholar
• Goldberg H, Miller RC, Bdah-Bortnyak R et al. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol. Oncol.108(2), 298–305 (2008).
   PubMed Web of Science ®Google Scholar
• Fader AN, Starks D, Gehrig PA et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol. Oncol.115(2), 244–248 (2009).
   PubMed Web of Science ®Google Scholar
• Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am. J. Surg. Pathol.16(6), 600–610 (1992).
   PubMed Web of Science ®Google Scholar
• Faratian D, Stillie A, Busby-Earle RM, Cowie VJ, Monaghan H. A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome. Int. J. Gynecol. Cancer16(3), 972–978 (2006).
   PubMed Web of Science ®Google Scholar
• Hamilton CA, Cheung MK, Osann K et al. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma. Gynecol. Oncol.103(2), 679–683 (2006).
   PubMedGoogle Scholar
• Kelly MG, O’Malley DM, Hui P et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol. Oncol.98(3), 353–359 (2005).
   PubMed Web of Science ®Google Scholar
• Schwartz PE. The management of serous papillary uterine cancer. Curr. Opin. Oncol.18(5), 494–499 (2006).
   PubMed Web of Science ®Google Scholar
• Memarzadeh S, Holschneider CH, Bristow RE et al. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int. J. Gynecol. Cancer12(5), 454–458 (2002).
   PubMed Web of Science ®Google Scholar
• Hamilton CA, Liou WS, Osann K et al. Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. Int. J. Radiat. Oncol. Biol. Phys.63(3), 839–844 (2005).
   PubMed Web of Science ®Google Scholar
• Chan JK, Loizzi V, Youssef M et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol. Oncol.90(1), 181–185 (2003).
   PubMed Web of Science ®Google Scholar
• Turner BC, Knisely JP, Kacinski BM et al. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys.40(1), 77–84 (1998).
   PubMedGoogle Scholar
• Gehrig PA, Van LL, Fowler WC. The role of omentectomy during the surgical staging of uterine serous carcinoma. Int. J. Gynecol. Cancer13(2), 212–215 (2003).
   PubMedGoogle Scholar
• Thomas MB, Mariani A, Cliby WA et al. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol. Oncol.107(2), 186–189 (2007).
   PubMedGoogle Scholar
• Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol.170(4), 974–979 (1994).
   PubMed Web of Science ®Google Scholar
• Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer71, 1534–1540 (1999).
   Google Scholar
• Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol. Oncol.55, S91–S96 (1994).
   Web of Science ®Google Scholar
• O’Hanlan KA, Levine PA, Harbatkin D et al. Virulence of papillary endometrial carcinoma. Gynecol. Oncol.37(1), 112–119 (1990).
   PubMedGoogle Scholar
• Wang W, DO V, Hogg R et al. Uterine papillary serous carcinoma: patterns of failure and survival. Aust. N. Z. J. Obstet. Gynaecol.49(4), 419–425 (2009).
   PubMed Web of Science ®Google Scholar
• Thomas MB, Mariani A, Cliby WA et al. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol. Oncol.107(2), 190–193 (2007).
   PubMed Web of Science ®Google Scholar
• Sutton GP, Brill L, Michael H, Stehman FB, Ehrlich CE. Malignant papillary lesions of the endometrium. Gynecol. Oncol.27(3), 294–304 (1987).
   PubMedGoogle Scholar
• Smith RS, Kapp DS, Chen Q, Teng NN. Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int. J. Radiat. Oncol. Biol. Phys.48(3), 767–778 (2000).
   PubMed Web of Science ®Google Scholar
• Gallion HH, van Nagell JR Jr, Powell DF et al. Stage I serous papillary carcinoma of the endometrium. Cancer63(11), 2224–2228 (1989).
   PubMedGoogle Scholar
• Frank AH, Tseng PC, Haffty BG et al. Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma. Cancer68(7), 1516–1519 (1991).
   PubMedGoogle Scholar
• Elit L, Kwon J, Bentley J et al. Optimal management for surgically stage 1 serous cancer of the uterus. Gynecol. Oncol.92(1), 240–246 (2004).
   PubMedGoogle Scholar
• Huh WK, Powell M, Leath CA et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy. Gynecol. Oncol.91(3), 470–475 (2003).
   PubMed Web of Science ®Google Scholar
• Mehta N, Yamada SD, Rotmensch J, Mundt AJ. Outcome and pattern of failure in pathologic stage I–II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int. J. Radiat. Oncol. Biol. Phys.57(4), 1004–1009 (2003).
   PubMed Web of Science ®Google Scholar
• Sutton G, Axelrod JH, Bundy BN et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol. Oncol.97(3), 755–763 (2005).
   PubMed Web of Science ®Google Scholar
• Sutton G, Axelrod JH, Bundy BN et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a Phase II study of the Gynecologic Oncology Group. Gynecol. Oncol.100(2), 349–354 (2006).
   PubMedGoogle Scholar
• Dubeshter B, Estler K, Altobelli K et al. High-dose rate brachytherapy for stage I/II papillary serous or clear cell endometrial cancer. Gynecol. Oncol.94(2), 383–386 (2004).
   PubMedGoogle Scholar
• Low JS, Wong EH, Tan HS et al. Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma. Gynecol. Oncol.97(1), 171–177 (2005).
   PubMed Web of Science ®Google Scholar
• Fakiris AJ, Moore DH, Reddy SR et al. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a Phase II Hoosier Oncology Group (HOG 97–01) study. Gynecol. Oncol.96(3), 818–823 (2005).
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Secord AA, Bae-Jump V et al. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol. Oncol.105(3), 677–682 (2007).
   PubMedGoogle Scholar
• Alektiar KM, Makker V, Bu-Rustum NR et al. Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I–II serous endometrial cancer. Gynecol. Oncol.112(1), 142–145 (2009).
   PubMedGoogle Scholar
• Mallipeddi P, Kapp DS, Teng NN. Long-term survival with adjuvant whole abdominopelvic irradiation for uterine papillary serous carcinoma. Cancer71(10), 3076–3081 (1993).
   PubMedGoogle Scholar
• Rosenberg P, Boeryd B, Simonsen E. A new aggressive treatment approach to high-grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer. Gynecol. Oncol.48(1), 32–37 (1993).
   PubMed Web of Science ®Google Scholar
• Levenback C, Burke TW, Silva E et al. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol. Oncol.46(3), 317–321 (1992).
   PubMed Web of Science ®Google Scholar
• Price FV, Chambers SK, Carcangiu ML et al. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol. Oncol.51(3), 383–389 (1993).
   PubMedGoogle Scholar
• Chambers JT, Chambers SK, Kohorn EI, Carcangiu ML, Schwartz PE. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide. Gynecol. Oncol.60(3), 438–442 (1996).
   PubMedGoogle Scholar
• Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol. Oncol.74(2), 272–277 (1999).
   PubMed Web of Science ®Google Scholar
• Bancher-Todesca D, Neunteufel W, Williams KE et al. Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma. Gynecol. Oncol.71(3), 344–347 (1998).
   PubMedGoogle Scholar
• Gitsch G, Friedlander ML, Wain GV, Hacker NF. Uterine papillary serous carcinoma. A clinical study. Cancer75(9), 2239–2243 (1995).
   PubMedGoogle Scholar
• Smith MR, Peters WA III, Drescher CW. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. Am. J. Obstet. Gynecol.170(6), 1677–1681 (1994).
   PubMed Web of Science ®Google Scholar
• Fitzgerald D, Rosenthal S. Uterine papillary serous carcinoma. Complete response to combination chemotherapy. Cancer56(5), 1023–1024 (1985).
   PubMedGoogle Scholar
• Resnik E, Taxy JB. Neoadjuvant chemotherapy in uterine papillary serous carcinoma. Gynecol. Oncol.62(1), 123–127 (1996).
   PubMedGoogle Scholar
• Ramondetta L, Burke TW, Levenback C et al. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol. Oncol.82(1), 156–161 (2001).
   PubMed Web of Science ®Google Scholar
• Fader AN, Drake RD, O’Malley DM et al. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer115(10), 2119–2127 (2009).
   PubMed Web of Science ®Google Scholar
• Fields AL, Einstein MH, Novetsky AP, Gebb J, Goldberg GL. Pilot phase II trial of radiation ‘sandwiched’ between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol. Oncol.108(1), 201–206 (2008).
   PubMed Web of Science ®Google Scholar
• Alektiar KM, Makker V, Bu-Rustum NR et al. Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I–II serous endometrial cancer. Gynecol. Oncol.112(1), 142–145 (2009).
   PubMedGoogle Scholar
• Dietrich CS, Modesitt SC, DePriest PD et al. The efficacy of adjuvant platinum-based chemotherapy in stage I uterine papillary serous carcinoma (UPSC). Gynecol. Oncol.99(3), 557–563 (2005).
   PubMedGoogle Scholar
• Lim P, Al KA, Gilks B, Wong F, Aquino-Parsons C. Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome. Cancer91(4), 752–757 (2001).
   PubMed Web of Science ®Google Scholar
• Kwon JS, Abrams J, Sugimoto A, Carey MS. Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging? Int. J. Gynecol. Cancer18(4), 820–824 (2008).
   PubMedGoogle Scholar
• Nguyen NP, Sallah S, Karlsson U et al. Prognosis for papillary serous carcinoma of the endometrium after surgical staging. Int. J. Gynecol. Cancer11(4), 305–311 (2001).
   PubMedGoogle Scholar
• Martin JD, Gilks B, Lim P. Papillary serous carcinoma – a less radio-sensitive subtype of endometrial cancer. Gynecol. Oncol.98(2), 299–303 (2005).
   PubMedGoogle Scholar
• Mantovani G, Proto E, Massa E et al. Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a Phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity. Int. J. Oncol.20(2), 419–427 (2002).
   PubMedGoogle Scholar
• Kwok TT, Sutherland RM. Differences in EGF related radiosensitisation of human squamous carcinoma cells with high and low numbers of EGF receptors. Br. J. Cancer64(2), 251–254 (1991).
   PubMed Web of Science ®Google Scholar
• Le TD, Yamada SD, Rutgers JL, DiSaia PJ. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with taxol and carboplatin. Gynecol. Oncol.73(3), 461–463 (1999).
   PubMedGoogle Scholar
• Quino-Parsons C, Lim P, Wong F, Mildenberger M. Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1A and 1B endometrial adenocarcinoma: treatment implications. Gynecol. Oncol.71(1), 83–86 (1998).
   PubMedGoogle Scholar
• Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am. J. Surg. Pathol.24(6), 797–806 (2000).
   PubMed Web of Science ®Google Scholar
• Vandenput I, Van CB, Capoen A et al. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br. J. Cancer101(2), 244–249 (2009).
   PubMed Web of Science ®Google Scholar
• Despierre E, Moerman P, Vergote I, Amant F. Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma? Int. J. Gynecol. Cancer16, S273–S277 (2006).
   PubMedGoogle Scholar